Sudarshan Pharma Shares in Focus After Promoter Warrant Conversion Adds 90 Lakh Equity Shares
Mumbai-based pharmaceutical company Sudarshan Pharma Industries Limited is likely to remain on investors’ radar after the company announced ...
Mumbai-based pharmaceutical company Sudarshan Pharma Industries Limited is likely to remain on investors’ radar after the company announced the allotment of 90 lakh equity shares following the conversion of preferential warrants held by promoter group entities.
In an exchange filing dated June 12, 2026, the company’s Warrants Committee approved the allotment of 90,00,000 equity shares with a face value of Re 1 each at an issue price of ₹16.983 per share, including a premium of ₹15.983 per share. The allotment was made pursuant to the conversion of 9,00,000 warrants that had originally been issued on a preferential basis to promoter category investors.
The conversion follows the receipt of the balance 75% warrant subscription amount aggregating to ₹11.46 crore from the allottees. Under SEBI regulations, warrant holders are required to pay 25% of the issue price upfront and the remaining 75% at the time of conversion.
